Vor Biopharma Inc

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapy for autoimmune diseases. Its product, telitacicept, is a fusion protein being developed for generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's disease, and IgA nephropathy. The company has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicept and related products. Vor Biopharma was incorporated in 2015 and is headquartered in Boston, Massachusetts.